Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Timing is everything: new trial seeks best moment for blood thinners after stroke

NCT ID NCT07139314

Disease control Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This study looks at the best time to start blood thinners in people with atrial fibrillation who had a stroke and then emergency treatment to remove a clot. Some patients develop bleeding in the brain after the procedure, and doctors want to know if starting blood thinners early or waiting is safer and more effective. The trial will enroll 240 adults and track strokes, bleeding, and death over 90 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18 years or over. 2. Clinical diagnosis of large vessel occlusion acute ischemic stroke. 3. Emergency endovascular treatment was performed within 24 hours of stroke onset. 4. Atrial fibrillation (including paroxysmal, persistent or permanent atrial fibrillation), confirmed by at least one of the following: 1. 12-lead ECG recording; 2. Inpatient ECG telemetry; 3. Prolonged ECG monitoring (e.g. Holter monitor); 4. Previously established diagnosis of atrial fibrillation verified by medical records. 5. CT or MRI demonstrating one of the following findings: 1. Parenchymatous hematoma type 1: defined as hematoma occupying less than 30% of the infarcted tissue, no substantive mass effect (Heidelberg classification); 2. Parenchymatous hematoma type 2: defined as heamtoma occupying 30% or more of the infarcted tissue, with obvious mass effect (Heidelberg classification); 3. Intracerebral hemorrhage outside the infarcted brain tissue or intracranial-extracerebral hemorrhage (Heidelberg classification). 6. Time from stroke onset to randomization ranged from 7 days to 4 weeks. 7. Written informed consent obtained from the patient or a legally authorized representative. Exclusion Criteria: 1. Atrial fibrillation due to reversible causes (e.g. thyrotoxicosis, pericarditis, recent surgery, or myocardial infarct). 2. Contraindication to the use of direct oral anticoagulants (DOACs): 1. Known allergy or intolerance to both factor Xa inhibitors and direct thrombin inhibitors; 2. Definite indication for vitamin K antagonist (VKA) treatment (e.g. mechanical heart valve, valvular atrial fibrillation); 3. Severe renal impairment (defined as creatinine exceeding 1.5 times of the upper limit of normal range) and significant hepatic dysfunction (defined as ALT or AST \> twice the upper limit of normal range) ; 4. Concomitant use of medications with significant interactions with DOACs, including azole antifungals, HIV protease inhibitors, or strong CYP3A4 inducers; 5. Baseline platelet count \< 100 x 109/L; 6. History of coagulopathy or systemic hemorrhage. 3. Prior DOAC use within 48 hours of stroke onset, or recent treatment with vitamin K antagonist (VKA) leading to INR ≥1.7 at randomization. 4. Pregnant or breastfeeding women, or positive pregnancy test at admission. 5. History of major surgery or severe trauma within 1 month prior to stroke onset. 6. History of active bleeding within 1 month prior to stroke onset (e.g. gastrointestinal bleeding, urinary tract bleeding). 7. Dual antiplatelet therapy at baseline, or strong likelihood of requiring dual antiplatelet therapy during the trial. 8. Evidence of cerebral amyloid angiopathy. 9. CT or MRI evidence of non-stroke pathology likely to account for the presenting clinical symptoms (e.g. mass lesion, encephalitis). 10. Modified Rankin scale (mRS) score \> 1 prior to stroke onset. 11. Inability to complete the 90-day follow-up. 12. Currently participating in another drug clinical trial. 13. Any other reason deemed by the investigator to make the patient unsuitable for participation in the trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atrial fibrillation ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation Ischemic stroke

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    37 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Aviation General Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Baoding Sixth Hospital

    RECRUITING

    Baoding, Hebei, China

  • Beijing Shijingshan Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Daliuta Experimental District People's Hospital of Shenmu City

    RECRUITING

    Shenmu, China

  • Fangcheng County People's Hospital

    RECRUITING

    Nanyang, Henan, China

  • Feicheng Hospital Of Shandong Yiyang Health Group

    RECRUITING

    Feicheng, Shandong, China

  • First Affiliated Hospital of Henan Polytechnic University

    RECRUITING

    Jiaozuo, China

  • Guoluo Prefecture People's Hospital

    RECRUITING

    Guoluo, China

  • Guoyao Northern Hospital (Baotou)

    RECRUITING

    Baotou, Shanxi, China

  • Heyuan People's Hospital

    RECRUITING

    Heyuan, Guangdong, China

  • Huanghua Municipal People's Hospital

    RECRUITING

    Huanghua, China

  • Jinan Zhangqiu District People's Hospital

    RECRUITING

    Jinan, Shandong, China

  • Laizhou City People's Hospital,

    RECRUITING

    Laizhou, Shandong, China

  • Linshu County People's Hospital

    RECRUITING

    Lishui, Shandong, China

  • Linyi People's Hospital

    RECRUITING

    Linyi, Shandong, China

  • Lushan County People's Hospital

    RECRUITING

    Pingdingshan, Henan, China

  • Ma'anshan People's Hospital

    RECRUITING

    Ma’anshan, Anhui, China

  • Nanyang Central Hospital

    RECRUITING

    Nanyang, Henan, China

  • Ningjin County People's Hospital

    RECRUITING

    Ningjin, China

  • Northern Jiangsu People's Hospital

    RECRUITING

    Yangzhou, Jiangsu, China

  • Ordos Central Hospital,

    RECRUITING

    Ordos, Neimenggu, China

  • Qilu Hospital of Shandong University

    RECRUITING

    Jinan, Shandong, China

  • Qinzhou First People's Hospital

    RECRUITING

    Qinzhou, Guangxi, China

  • Queshan County People's Hospital

    RECRUITING

    Zhumadian, Henan, China

  • Ren Shou County People's Hospital

    RECRUITING

    Renshou, China

  • ShanXi Cardiovascular Hospital

    RECRUITING

    Taiyuan, Shanxi, China

  • The Affiliated Hospital of Xuzhou Medical University

    RECRUITING

    Xuzhou, China

  • The First Affiliated Hospital of Harbin Medical University

    RECRUITING

    Harbin, Heilongjiang, China

  • The Hongda Hospital of Jiamusi University

    RECRUITING

    Jiamusi, Heilongjiang, China

  • The Second Affiliated Hospital of Kunming Medical University

    RECRUITING

    Kunming, Yunnan, China

  • Tianyou Hospital, Wuhan University of Science and Technology

    RECRUITING

    Wuhan, Hubei, China

  • Xinyang Central Hospital

    RECRUITING

    Xinyang, Henan, China

  • Xiuyan Central Hospital

    RECRUITING

    Xiuyan, China

  • Xuanwu Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100053, China

  • Yantai Yeda Hospital

    RECRUITING

    Yantai, Shandong, China

  • Yingkou Central Hospital

    RECRUITING

    Yingkou, Liaoning, China

  • Zhangzhou Municipal Hospital of Fujian Province

    RECRUITING

    Zhangzhou, Fujian, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.